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Abstract 
Background 
Studies in haemodialysis patients suggest that hyponatraemia is associated with 
increased mortality, however, results from peritoneal dialysis (PD) patients are 
discordant. We wished to establish whether there was an association between serum 
sodium and mortality risk in PD patients. 
 
Methods 
We analysed 3108 PD patients enrolled at day 90 of renal replacement therapy (RRT) 
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into the UK Renal Registry data base with available serum sodium measurements (in 3 
groups: ≤137, 138-140, ≥ 141 mmol/l) who were then followed up until death, or the 
censoring date (31st Dec 2012). Analysis used Cox-regression with adjustment for age, 
sex, year of starting RRT, primary renal disease, serum albumin, smoking, and co-
morbidities.  
  
Results  
Unadjusted mortality rates were 118.6/1000 person years (py), 83.4/1000 py, and 
83.5/1000 py for the lowest, middle and highest serum sodium tertiles, respectively. 
After adjustment for covariates, patients in the lowest serum sodium group had almost 
50% increased risk of dying compared to those with the highest serum sodium (HR 
1.49, CI:1.28-1.74), with a graded association between serum sodium and mortality. The 
association of serum sodium with mortality varied by age (p interaction <0.001), and 
whilst this association attenuated after adjustment for confounding variables in the 
older age groups (55 – 64, and >65 years), it remained in the younger age group of 18-
54 years (HR 2.24(1.36-3.70) in the lowest compared to the highest sodium tertile).  
 
Conclusions 
Lower serum sodium concentrations at the start of RRT in PD patients are associated 
with increased risk of mortality. Whilst this association may well be due to confounding 
in the older age groups,  the persistent strong association between hyponatraemia in 
the younger age group after adjustment for the available confounders suggests that 
prospective studies are required to assess whether active intervention to maintain 
serum sodium changes outcomes. 
 
Introduction 
Hyponatraemia in the general population is well recognised to be associated with 
an increased risk for mortality [1]. Hyponatraemia is the commonest electrolyte 
disorder encountered in hospitalised patients and may develop due to increased renal 
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water retention secondary to vasopressin release (e.g. in patients with chronic liver 
disease and cardiac failure), or a failure to adequately excrete water as in cases of 
inappropriate vasopressin secretion, which may be drug induced, or alternatively due to 
polydipsia and reduced dietary sodium intake excessive water or beer ingestion, and 
also due to increased sodium losses associated with hypovolaemia from diuretics and 
purgatives [2]. Inflammatory states with increased secretion of IL-6 and C reactive 
protein (CRP) have also been documented to be associated with hyponatraemia due to 
vasopressin release [3]. 
Patients with chronic kidney disease may also develop hyponatraemia from 
either a relative excessive water intake to sodium, or relative greater loss of sodium 
compared to water. As with the general population there are several large observational 
studies reporting that pre-haemodialysis hyponatraemia is independently associated 
with increased risk of mortality for haemodialysis patients [4,5]. Whether this risk for 
mortality is directly attributable to hyponatraemia, and reduced body sodium stores, or 
whether hyponatraemia is acting as a surrogate for an inflammatory state and 
increased endothelial permeability remains to be determined. Although there are 
studies reporting no increased mortality with lower pre-haemodialysis serum sodium 
values [6]. However the situation is less clear for peritoneal dialysis patients, with one 
recent report suggesting an increased risk for mortality for prevalent peritoneal 
dialysis patients with a lower time-averaged serum sodium [7], whereas two others did 
not find any statistically significant association between lower serum sodium 
concentrations at either the start of peritoneal dialysis or intermittent episodes during 
treatment with peritoneal dialysis and mortality [8,9] . The one previous study 
reporting increased overall mortality with lower time averaged serum sodium 
concentrations potentially had a number of confounding factors, ranging from patient 
selection bias, through to censoring patients transferring from peritoneal dialysis, and 
statistical analysis. As such we wished to investigate whether hyponatraemia in 
peritoneal dialysis patients is associated with an increased mortality risk by using data 
from the UK Renal Registry.  
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Methods 
In the UK data is collected on dialysis patients from the 71 National Health 
Service dialysis centres in England, Wales and Northern Ireland by the UK Renal 
Registry after patients have been treated by dialysis for 90 days. This 90 day cut off 
follows the USRDS data collection designed to exclude cases of acute kidney injury.  
We analysed data for incident peritoneal dialysis (PD) patients starting dialysis 
between 2000 and 2012 from centres reporting to the UK renal registry (UKRR). We 
restricted the analysis to those dialysis centres which had > 85% completeness of 
serum sodium data at the time of enrolment into the UKRR database. The lack of 
returns of serum sodium data for a subset of centres relates to their local data 
extraction routines.  
Data from 14,920 patients starting any form of renal replacement therapy 
(haemodialysis, PD and transplantation) in the UK were collected including age at start 
of renal replacement therapy, sex, cause of primary renal disease, ethnic group, serum 
albumin, serum sodium, date of death, smoking status and comorbidity data (angina, 
non-coronary angioplasty, claudication, chronic obstructive airways disease, diabetes 
not causing end stage kidney disease, ischaemic and neuropathic ulcers, chronic liver 
disease, malignancy, previous myocardial infarction both within the last 3 months or 
more than 3 months from the date of enrolment, previous coronary artery bypass 
grafting (CABG), or percutaneous coronary intervention (PCI), amputation for 
peripheral vascular disease (PVD) and symptomatic cerebrovascular disease. We also 
collected data on the dates of when dialysis started and ended, and changes in 
treatment modality. Cardiac disease as a co-morbidity variable was created by 
combining angina, previous myocardial infarction within the last 3 months, previous 
myocardial infarction more than 3 months ago, previous CABG or PCI. Peripheral 
vascular disease as a co-morbidity was created by combining non-coronary angioplasty, 
claudication and ischaemic or neuropathic ulcers. 
552 out of the 14,920 patients died before completing 90 days on 
haemodialysis, peritoneal dialysis or transplantation and were therefore were removed 
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from analysis.  We then restricted the data analysis to only those patients treated by 
PD at the time of enrolment by the UKRR, which left 3108 patients (Figure 1).  
Rather than predefining patients according to serum sodium concentrations we 
grouped patients into 3 groups based on the distribution of their serum sodium 
concentrations; ≤137, 138-140, and ≥ 141 mmol/l. 
Patients were then followed up from enrolment at 90 days after starting dialysis 
until death, or the censoring dates (either the last day these patients observed or the 
date the cohort was censored on the 31st of December 2012). Patients transferring 
modality to transplantation or to other UK renal dialysis centres were not censored to 
prevent introducing a selection bias towards unfit patients (those who are not 
transplanted). 
 Serum sodium measurements across different UK health care facilities are 
routinely standardised through the UK national external quality assessment body 
(NEQAS) for clinical chemistry laboratories, using an indirect potentiometer method. 
The UKRR collected serum sodium results electronically within the first quarter once 
patients had been established on peritoneal dialysis for 90 days, and the first serum 
sodium result after day 90 was used for this study... 
 
Statistical Analysis 
Descriptive analysis was conducted to determine the association between 
different potential predictors of mortality at baseline. The Chi square (χ2) test was 
used to assess associations between binary and categorical variables. Linear regression 
was used to examine the association of continuous explanatory variables (age and serum 
albumin) with the main exposure (serum sodium). In cases of missing data across 
categories of serum sodium and death, a missing data indicator variable was created 
for each missing data entry. The Z test was used to compare proportions of missing 
data within “dead” and “alive” groups of the outcome variable. The distribution of 
missing data across the main exposure categories was described after performing 
cross tabulation with missing indicator variables for each covariate.  
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Kaplan-Meier graphs (log rank test) were used to analyse patient survival 
according to serum sodium group. A Cox-regression model was used to examine the 
relationship between mortality and serum sodium concentration, while accounting for 
facility clustering effect using robust standard errors with time-on-study as the time-
scale and baseline age as a covariate. Proportional hazard assumption for Cox model was 
investigated using two methods. Firstly graphs of -log (-log (survival)) against the log of 
time for each explanatory variable were plotted, and secondly Poisson models were 
fitted with interaction term between these explanatory variables and follow-up time 
obtained from lexis expansion. The graphical methods showed non-proportionality for 
the Cox hazard assumption for the serum sodium concentration and significant 
interaction with the follow-up time in the Poisson model, but when interaction terms 
between age and cause of kidney failure and age and comorbidities were included the 
hazard proportional assumption was valid (interaction between follow-up time and 
sodium disappeared) which justified the use of cox models. In total seven models were 
used, with each model building on the previous version (model 1: crude association of 
serum sodium with mortality; model 2: adjusted for sex and age, model 3: adjusted for 
period of starting PD, model 4: adjusted for primary renal disease, model 5: adjusted 
for serum albumin, model 6: adjusted for smoking and also including an interaction term 
between age and cause of primary renal disease while adjusting for age as continuous 
variable to account for potential residual confounding, and finally model 7: adjusted for 
comorbidities.  Analysis was initially undertaken on the full cohort, and then restricted 
to the Caucasian cohort to avoid any potential bias due to patients from the ethnic 
minorities. Not all variables were recorded in every patient and sequential restrictions 
were implemented to ensure that comparison of hazard ratios were reviewed between 
similar cohorts albeit with some loss of power. Models with similarly available data on 
primary renal disease, serum albumin, smoking and co-morbidities were compared to 
understand the confounding effects of these covariates in similar cohorts. As age 
showed a significant interaction with serum sodium, then results were stratified by age 
categories. Statistical significance was taken at the p<0.05 level. 
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Ethical Approval 
The UK Renal Registry has a UK wide ethical approval granted by the UK 
government secretary of state for health, through the UK patient information advisory 
group to collect patient data without individual patient consent. The study was 
approved by the London School of Tropical Medicine & Hygiene research ethics 
committee reference number 7565.  
  
Results 
The mean serum sodium for the 3108 new starters to peritoneal dialysis was 
138.5±3.7mmol/l (range 120- 149). Patients were divided into tertiles, according to 
their serum sodium concentration (table 1). There were more proportionally more 
women and diabetics in the group with the lowest serum sodium concentrations, and 
relatively more patients starting PD between 2005 and 2009, than other eras. The 
serum albumin was also lower in the lower serum sodium tertiles, mean 36.5 g/l (95% 
confidence limits 35.4-35.8), compared to 37.4 g/l (37.2-37.6) in the middle sodium 
group and 38.3g/l (38.1-38.5) in the highest serum sodium group, p<0.001.  However, 
there were no obvious association of serum sodium with age, or different types of co-
morbidity. 
The median follow up time was 3.2 (range: 0-12.7) years, with a total survival 
time of 11,872 person-years. Survival time after enrolment was greater for those 
patients in the highest and middle serum sodium cohorts, compared to those in the 
lowest cohort (figure 2). Estimated crude mortality rate was 118.63 per 1000 person 
years in the lowest serum sodium cohort, 83.36 per 1000 person years in the middle 
serum sodium cohort and 83.49 per 1000 person years in the highest serum sodium 
cohort. Patients with the lowest serum sodium group had around 50% increased risk of 
dying compared to those with the highest serum sodium cohort (HR 1.49, CI:1.28-1.74) 
while those who were in the middle serum sodium cohort had only 6%, non-significant 
increased risk of death (HR1.06, CI:0.90-1.26). As expected mortality was also 
associated with increasing age, male sex, diabetic nephropathy as primary renal disease, 
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co-morbidities, Caucasian ethnicity, and earlier era of starting dialysis, smoking and 
lower serum albumin (table 2).  
There was a strong interaction between sodium categories and age (p value for 
interaction <0.001). Mortality rate decreased by 17% for each 3.6 mmol/l increase in 
serum sodium ((HR: 0.83 (CI 0.76-0.90).  On crude analysis when sodium was entered as 
a continuous variable, there was a very strong evidence of association between 
mortality and serum sodium level (p<0.001). Results are shown in each age stratum 
separately (table 3). For the youngest age group, the association of a lower serum 
sodium with increased risk for mortality remained after adjusting for sex, era starting 
PD, primary renal disease, serum albumin, smoking and co-morbidities. However, when 
adjusting for these variables amongst middle and older aged groups the association of 
serum sodium with mortality was markedly attenuated, but remained significant 
(Hazard ratio 0.97, p=0.02). 
To exclude any potential effect by diabetes, we then re-analysed the data by 
excluding patients who had diabetic nephropathy as their cause of renal disease. The 
association between a lower serum sodium, whether modelled as a continuous or 
categorical variable remained and mortality remained strongly significant (table 4).  
Additional tables of analyses are presented in the on-line appendix. 
 
Discussion 
 Our study reports an increased mortality rate associated with 
hyponatraemia in PD patients at the time of enrolment into the UKRR. There was a 3% 
reduction in mortality for each 3.6 mmol/l increase in serum sodium. This association 
between mortality and hyponatraemia was modified by age, with our younger age group 
having more than a twofold increased risk of death, even after adjusting for age and 
other covariates associated with mortality. Whereas some studies have reported an 
increased mortality with increasing serum sodium [10], we found a relative protective 
effect of higher serum sodium concentrations, in keeping with the DOPPS report in 
haemodialysis patients [6] and one smaller study in peritoneal dialysis patients [11]. 
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 Hyponatraemia is a recognised risk factor for mortality in the general 
population and patients admitted to hospital [1]. Traditionally this risk has been 
ascribed to underlying co-morbidity, such as congestive cardiac failure, cirrhosis and 
tumour induced inappropriate ADH syndrome.  The situation for patients with chronic 
kidney disease may be somewhat more complex, with reports of both hyponatraemia 
and also hypernatraemia associated with increased mortality [10], and although there 
are reports of increased risk for mortality in hyponatraemic haemodialysis patients 
[4,5], these reports are biased towards more co-morbid patients because they 
censored patients who were transplanted from the analyses. Our analyses were more 
conservative – if we had censored the patients who were transplanted we would have 
biased our sample to the more ill population, and similarly if we had removed all patients 
with technique failure from the mortality outcome analysis we would have biased our 
sample to a more healthy population. Incident haemodialysis patients, who were 
hyponatraemic after adjusting serum sodium measurements for diabetic control were 
reported to have an increased risk for death [12], whereas others have reported that 
hyponatraemia does not confer any additional risk for mortality [6] and also in non-
haemodialysis diabetic patients [13]. Similarly some studies in haemodialysis patients 
reported that mortality reduced for each 4 mmol/l increase in serum sodium [4], 
although others reported no survival advantage once the serum sodium reached 145 
mmol/l [6]. 
 We found that the mortality risk associated with hyponatremia was 
greatest for the younger age group, compared to the older and middle age groups, 
whereas other studies have not reported any age effect [7,8]. There was also a higher 
proportion of patients in the lowest serum sodium cohort in the younger age group 
(45%) compared to the middle (21%) and older (34%) age groups. The higher effect 
estimate and the higher proportion of hyponatraemia in the younger age group might be 
partially explained by the higher proportion of patients with diabetic nephropathy in 
this group (50%) compared to middle (24%) and the older (25%) age groups. There has 
been debate as to the effect of increasing glucose concentrations on the measurement 
of serum sodium using indirect potentiometer and flame photometry [14], and potential 
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correction factors for adjusting serum sodium for glucose, with some studies reporting 
no difference in serum sodium concentration between diabetic and non-diabetic dialysis 
patients [6, 15]. Previous observational studies have suggested greater inter-dialytic 
weight gains in diabetic patients [16], and greater ratio of extracellular to total body 
water in diabetic peritoneal dialysis patients [17], suggesting that hyponatraemia in 
diabetic dialysis patients may have an over hydration component, perhaps due to 
increased thirst. However, when we repeated our analyses after excluding those 
patients who had diabetes as the primary cause of end-stage kidney disease, the 
association between lower serum sodium and mortality remained, as did the effect of 
age. As such this association cannot simply be explained by diabetes. 
 As expected co-morbidity increased with age, being highest in the older age group 
(53%) compared to the middle (25%) and the younger (22%), whereas serum albumin 
fell with increasing age. Previous studies in hyponatraemic patients reported an 
association with lower serum albumin and malnutrition [8,18] and relative extracellular 
water over-hydration [19] due to loss of intracellular water and body cell mass [20,21]. 
The UKRR does not collect data on nutritional status or body composition, even so our 
data would support a role for inflammation and malnutrition in inducing hyponatraemia, 
as serum albumin concentrations were lowest in the lowest serum sodium cohort, 
although we have no corroborating measures of inflammation in terms of C reactive 
protein or body composition data, relating either to extracellular water excess or loss 
of lean body tissues. Studies of acutely ill peritoneal dialysis patients admitted with 
peritonitis have reported an association between lower serum sodium in the acute 
situation and worse outcomes [22]. 
When adjusting for co-morbidities [23], there was a greater increase in HR for lower 
sodium and mortality in the younger patients and to a lesser extent for the older age 
group, suggesting a confounding effect of increasing comorbidity with age.  Mortality 
rate was higher in the young age groups, which was only partially explained by the 
higher proportion of diabetes as a cause of primary renal disease among the younger 
age group and its associated ill health and social deprivation [24]. This effect 
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modification of age and confounding by covariates, in particular diabetes and albumin, 
may help to explain the discordant results from other studies in peritoneal dialysis 
patients, recently reported in studies from Korean and Taiwan [7,9].  
 As with any retrospective observational study, our study has a number of 
limitations. Outcome data was missing in 5.6% of cases, but this was equally distributed 
between the three sodium concentration cohorts, and coupled with similar distribution 
of follow up time across the cohorts it is unlikely to have biased the results. We 
adjusted for comorbidities, as they are important predictors for mortality, to enable a 
less biased conclusion to be reached. Some subgroup analyses were small and had wide 
confidence intervals, however the size and direction of effect estimates remained 
consistent. The UKRR does not collect data on the type of peritoneal dialysis solutions 
used by patients, and as such we were unable to adjust for icodextrin usage [19]. 
However, icodextrin would only be a potential confounder if icodextrin usage had been 
restricted to the younger patients. Similarly the UKRR does not collect data on residual 
renal function, or the prescription of diuretics and anti-hypertensives. We cannot 
exclude that restoration of haemoglobin concentrations in patients starting PD might 
be associated with restoration of other nutritional parameters. However as the vast 
majority of patients starting PD in the UK have pre-dialysis nephrology care with 
access to erythropoietin stimulating agents (ESAs), and clinical guideline targets for 
haemoglobin concentration, makes this less likely. As the UKRR does not collect data on 
ESA usage or iron administration; we were unable to determine erythropoietin 
resistance, and as such cannot exclude an association with hyponatraemia and mortality 
due to an association with serum albumin. 
In studies which have reported on time averaged serum sodium, lower serum sodium is 
associated with lower residual renal function and increased peritoneal ultrafiltration 
[8]. Whether this association is due to changes in peritoneal dialysis prescription and 
exposure to higher glucose peritoneal dialysates remains to be determined. Even if we 
had data on type of dialysate prescription over time the issue is that adjusting the 
associations for changes in prescription over time would be adjusting for variables on 
the causal pathway. We were also not able to determine volume status, but previous 
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studies have reported that only a minority of peritoneal dialysis patients with 
hyponatraemia are overhydrated [7,8]. Similarly we were unable to access data on 
dietary sodium intake, and the UKRR does not collect data on hydration status of 
peritoneal dialysis patients. Compared to previous studies which used time averaged 
serum sodium [22], we chose only to analyse the first serum sodium measured after 
starting peritoneal dialysis to reduce bias from changes in residual renal function, 
peritoneal dialysis prescription and censoring due to modality changes. More 
importantly time averaged serum sodium is likely to be biased by hospital admissions 
with acute inter-current illnesses, as these are more likely to be associated with a 
lower serum sodium values, and also increased number of measurements. 
 Our study shows that lower serum sodium concentrations at the start of renal 
replacement therapy in peritoneal dialysis patients is associated with increased risk of 
mortality. As with any observational study causality cannot be established, however the 
persistent strong association between hyponatraemia in the younger age group after 
adjustment for the available confounders requires more investigation. Prospective 
studies are required to determine whether active interventions designed to sustain 
serum sodium concentrations improve patient outcomes. 
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Figure 1: Flow diagram to show patient study recruitment 
 
Figure 2: Patient Kaplan Meier survival graph 
 
 
 
Table 1: Patients divided according to serum sodium at enrolment by UK Renal Registry 
after day 90 of peritoneal dialysis. Age and other variables at the time of enrolment, 
patients were also divided according to age and era of starting peritoneal dialysis. . 
Results as number, percentage (%), mean and 95% confidence limits) unless otherwise 
stated. Diabetic nephropathy (DN), Co-morbidities : cardiovascular disease (CVS), 
peripheral vascular disease (PVD), chronic obstructive airways disease (COPD), chronic 
liver disease (CLD), diabetes mellitus (DM) not causing renal failure, symptomatic 
cerebrovascular disease (CerebVD), Co-morbidity (Comorbid). *p value for association 
 
Variable  N (%) Serum Sodium  
<138 
mmol/l 
138-140 
mmol/l 
> 140mmol/l *p 
value 
Patients  3,108 1061 
(35.5%) 
1006 
(33.6%) 
925 
(30.9%) 
 
Age yr 
 
 
 
3,108 
 
58.4(57.4-
59.3%) 
58.5(57.5-
59.5%) 
58.2(57.2-
59.4%) 
0.924 
 
 18-54 yr 1164(37.5%) 401(37.8%) 378(37.6%) 346(37.4%) 0.992 
 55-64 yr 676(21.8%) 230(21.7%) 215(21.4%) 206(22.3%)  
 ≥65 yr 1268(40.8%) 430(40.5%) 413(41.1%) 373(40.3%)  
Sex Male 1949(62.7%) 607(57.3%) 628(62.4%) 648(70.1%) <0.001 
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 Female 1159(37.3%)  453(42.7%)  378(37.6%) 277(30.0%)  
ethnicity Asian 131(4.4%) 56(5.5%) 46(4.8%) 25(2.8%) 0.098 
 Black 60(2.0%)  17(1.7%) 18(1.9% 23(2.6%)  
 White 2751(92.4%) 925(91.6%) 891(92.1%) 829(93.3%)   
 Other  37(1.2%) 12(1.2%) 13(1.3%) 12(1.4%)  
Era 2000-2004 774(24.9%) 570(25.8%) 642(29.3%) 433(22.4%) <0.001 
 2005-2009 1616(51.9) 1248(56.4%
) 
1129(51.6%) 1107(57.2%)  
 2010-2012 718(23.1%) 394(17.8%) 418(19.1%) 396(20.5%)  
Primary 
Renal 
DN 551(18.7%)  266(26.7%) 146(15.1%) 110(12.6%)  
<0.001 
Disease Other 2404(81.3%) 732(73.4%) 822(84.9%) 766(87.4%)  
Smoking Nonsmoker 1488(86.3%) 497(84.5%) 534(86.7%) 414(87.5%) 0.332 
 Smoker 237(13.7%) 91(15.5%) 82(13.3%) 59(12.5%)  
CVS Absent 1458(83.3%) 498(83.8%) 515(83.1%) 405(83.3%) 0.935 
 Present  293(16.7%) 96(16.2%) 105(16.9%) 81(16.7%)  
PVD Absent 1664(95.3%) 558(94.3%) 591(95.3% 466(96.3%) 0.298 
 Present  83(4.7%)  34(5.7%) 29(4.7%) 18(3.7%)  
COPD Absent 1666(95.9%) 562(95.3%) 571(95.9%) 467(96.9% 0.396 
 Present  71(4.1%) 28(4.8%) 25(4.1%) 15(3.1%)  
DM Absent 1640(94.4% 555(94.1%) 576(93.7%) 462(95.5%) 0.420 
 Present  98(5.6%) 35(5.9% 39(6.3% 22(4.6%)  
CLD Absent 1723(98.6%) 582(98.3%) 612(98.9%) 478(98.6%) 0.712 
 Present   24(1.4%) 10(1.7%) 7(1.1%) 7(1.4%)  
Cancer Absent 1582(90.6%) 542(91.4%) 562(90.8% 432(89.3%) 0.474 
 Present  165(9.4%) 51(8.6%) 57(9.2%) 52(10.7%)  
CerebVD Absent 1618(93.0%)  547(92.9%) 575(93.0%) 449(93.0%) 0.993 
 Present  122(7.0%) 42(7.1%) 43(7.0%) 34(7.0%)  
Comorbid Absent 1114(63.4%) 375(63.0%) 393(63.2%) 314(64.3%) 0.890 
1 or more Present 642(36.6%) 220(37.0%) 229(36.8%) 174(35.7%)  
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Table 2 : Multivariable analysis (adjusted for age and sex only): Association of 
covariates with mortality in the cohort of patients on peritoneal dialysis at start of 
renal replacement therapy (RRT) adjusted for sex and age. Serum sodium (sodium), age 
at start of RRT (age), Diabetic nephropathy (DN) as primary cause or renal disease. 
Hazard ratio (HR). 
 
Variable category Rate time per 1000 
patient yrs 
HR ( 95 % CI) P value 
Sodium  continuous   0.95(0.93-0.97) <0.001 
Sodium  <138  118.63 3.87 1.49(1.28-1.74) <0.001 
mmol/l 138-140 83.36 3.99 1.06(0.90-1.26)  
 > 140 83.49 3.57 1  
Albumin g/l continuous    0.92(0.91-0.94) <0.001 
RRT start  2000-2004 107.0 4.4 1 0.002 
 2005-2009 93.0 6.4 0.80(0.68-0.93)  
 2010-2012 75.7 1.1 0.63(0.50-0.82)  
Age yrs 18-54 34.06 5.31 1 <0.001 
 55-64 88.80 2.67 2.72(2.18-3.39)  
 ≥65 187.16 3.89 5.68(4.57-7.07)  
Sex Male 103.88 7.4 1 <0.001 
 Female 84.51 4.51 0.82(0.73-0.92)  
Ethnicity White 91.54 10.70 1 <0.001 
 Asian 59.45 0.52 0.84(0.60-1.17)  
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 Black 32.11 0.28 0.50(0.23-1.10)  
 Other 37.96 0.16 0.72(0.52-0.99)  
DN Absent 86.86 9.65 1 <0.001 
DN Present 126.06 1.90 1.66(1.29-2.15)  
Smoker No 75.94 6.11 1 0.130 
 Yes 92.38 0.91 1.33(0.92-1.91)  
No co-morbidity Absent 50.25 4.76 1 <0.001 
≥ 1 co-morbidity Present 135.38 2.39 1.82(1.35-2.45)  
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Table 3: Crude and sequentially adjusted hazard ratios (HR) with 95% confidence 
intervals of serum sodium on long-term survival after 90 days from the start of 
peritoneal dialysis, stratified by age category. Model 1 – adjusted for age as a 
continuous variable and sex, Model 2 – additionally adjusted for year of starting renal 
replacement therapy, Model 3 additionally adjusted for primary renal disease, Model 4 
additionally adjusted for serum albumin, Model 5 additionally adjusted for smoking, 
Model 6 additionally adjusted for co-morbidity 
 
Patient age   Serum Sodium mmol/l  
18-54years  No 
patients 
No of 
patients 
with the 
event 
< 138 138 -140 >140 p  
value 
unadjusted 1125 111 2.18(1.48-
3.22) 
1.04(0.58-
1.86) 
1 <0.001 
Model 1 1125 111 2.20(1.49-
3.23) 
1.03(0.55-
1.91) 
1 <0.001 
Model 2 1125 111 2.18(1.48-
3.20) 
1.02(0.54-
1.91) 
1 <0.001 
Model 3 1073 102 1.77(1.18-
2.65) 
1.03(0.56-
1.91) 
1 <0.001 
Model 4 1057 99 1.53(1.01-
2.32) 
0.93(0.48-
1.83) 
1 0.009 
Model 5 611 45 1.99(1.20-
3.29) 
1.43(0.75-
2.74) 
1 0.007 
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Model  6 609 45 2.24(1.36-
3.70) 
1.52(0.80-
2.88) 
1 0.002 
55-64years       
Unadjusted 651 164 1.45(1.01-
2.07) 
1.02(0.65-
1.58) 
1 0.103 
Model 1 651 164 1.46(1.01-
2.12) 
1.03(0.65-
1.61) 
1 0.047 
Model 2 651 164 1.44(1.01-
2.06) 
1.00(0.64-
1.57) 
1 0.034 
Model 3 619 151 1.18(0.86-
1.61) 
0.95(0.63-
1.44) 
1 0.261 
Model 4 614 148 1.05(0.78-
1.44) 
0.87(0.53-
1.43) 
1 0.571 
Model 5 347 62 1.02(0.50-
2.08) 
1.35(0.75-
2.44) 
1 0.368 
Model 6 346 62 1.00(0.48-
2.08) 
1.28(0.69-
2.38) 
1 0.462 
65+years       
Unadjusted 1216 452 1.32(1.12-
1.55) 
1.10 (0.93-
1.30) 
1 <0.001 
Model 1 1217 452 1.30(1.12-
1.52) 
1.07 (0.90-
1.26) 
1 0.002 
Model 2 1217 452 1.28(1.10-
1.49) 
1.05 (0.90-
1.23) 
1 0.003 
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Model 3 1150 422 1.30(1.11-
1.53) 
1.11 (0.94-
1.31) 
1 0.007 
Model 4 1139 418 1.12(0.95-
1.33) 
1.06 (0.87-
1.27) 
1 0.399 
Model 5 693 219 1.14(0.92-
1.42) 
1.10 (0.87-
1.39) 
1 0.491 
Model 6 693 219 1.20(0.95-
1.52) 
1.11 (0.88-
1.39) 
1 0.327 
 
Footnote: models adjusted for comorbidities included an interaction term between 
comorbidities and age, models adjusted for primary renal disease (PRD) included an 
interaction term for PRD 
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Table 4: Multivariable analysis (adjusted for age and sex only) in patients without a 
diagnosis of diabetes 
 
Variable category Rate time per 1000 
patient yrs 
HR ( 95 % CI) P value 
Sodium (continuous)    0.95 (0.93-0.97) <0.001 
Sodium (categorical -mmol/l) 
<120-137  114.8 2.83 1.54 (1.30-1.81) 
<0.001 138-140 97.0 3.30 1.13 (0.92-1.38) 
≥ 141-149 75.5 3.12 1 
Albumin g/l (continuous)    0.95 (0.93-0.96) <0.001 
RRT start  
2000-2004 100.11 3.62 1 
0.008 2005-2009 84.95 5.11 0.78 (0.64-0.95) 
2010-2012 74.15 0.88 0.66 (0.50-0.87) 
Age yrs 
18-54 23.93 4.30 1  
<0.001 55-64 76.27 2.12 3.35 (2.64-4.24) 
≥65 187.85 3.17 8.20 (6.09-11.04) 
Sex 
Male 99.65 5.85 1 
0.037 
Female 74.12 3.75 0.80 (0.79-0.99) 
Ethnicity 
White 84.91 8.66 1 
<0.001 
Asian 48.01 0.35 0.78 (0.58-1.05) 
Black 23.04 0.26 0.46 (0.20-1.10) 
Other 7.28 0.14 0.20 (0.04-0.93) 
Smoker 
No 70.0 4.93 1 
0.524 
Yes 69.18 0.69 1.13 (0.78-1.62) 
No co-morbidity Absent 45.19 4.12 1 
<0.001 
≥ 1 co-morbidity Present 134.58 1.60 1.78 (1.30-2.45) 
 
